Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.
Perera RM, Narita Y, Furnari FB, Gan HK, Murone C, Ahlkvist M, Luwor RB, Burgess AW, Stockert E, Jungbluth AA, Old LJ, Cavenee WK, Scott AM, Johns TG. Perera RM, et al. Among authors: murone c. Clin Cancer Res. 2005 Sep 1;11(17):6390-9. doi: 10.1158/1078-0432.CCR-04-2653. Clin Cancer Res. 2005. PMID: 16144944
Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478.
Johns TG, Luwor RB, Murone C, Walker F, Weinstock J, Vitali AA, Perera RM, Jungbluth AA, Stockert E, Old LJ, Nice EC, Burgess AW, Scott AM. Johns TG, et al. Among authors: murone c. Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15871-6. doi: 10.1073/pnas.2036503100. Epub 2003 Dec 15. Proc Natl Acad Sci U S A. 2003. PMID: 14676326 Free PMC article.
A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake.
Scott AM, Lee FT, Jones R, Hopkins W, MacGregor D, Cebon JS, Hannah A, Chong G, U P, Papenfuss A, Rigopoulos A, Sturrock S, Murphy R, Wirth V, Murone C, Smyth FE, Knight S, Welt S, Ritter G, Richards E, Nice EC, Burgess AW, Old LJ. Scott AM, et al. Among authors: murone c. Clin Cancer Res. 2005 Jul 1;11(13):4810-7. doi: 10.1158/1078-0432.CCR-04-2329. Clin Cancer Res. 2005. PMID: 16000578 Clinical Trial.
A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors.
Scott AM, Lee FT, Tebbutt N, Herbertson R, Gill SS, Liu Z, Skrinos E, Murone C, Saunder TH, Chappell B, Papenfuss AT, Poon AM, Hopkins W, Smyth FE, MacGregor D, Cher LM, Jungbluth AA, Ritter G, Brechbiel MW, Murphy R, Burgess AW, Hoffman EW, Johns TG, Old LJ. Scott AM, et al. Among authors: murone c. Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4071-6. doi: 10.1073/pnas.0611693104. Epub 2007 Feb 28. Proc Natl Acad Sci U S A. 2007. PMID: 17360479 Free PMC article. Clinical Trial.
A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen.
Scott AM, Tebbutt N, Lee FT, Cavicchiolo T, Liu Z, Gill S, Poon AM, Hopkins W, Smyth FE, Murone C, MacGregor D, Papenfuss AT, Chappell B, Saunder TH, Brechbiel MW, Davis ID, Murphy R, Chong G, Hoffman EW, Old LJ. Scott AM, et al. Among authors: murone c. Clin Cancer Res. 2007 Jun 1;13(11):3286-92. doi: 10.1158/1078-0432.CCR-07-0284. Clin Cancer Res. 2007. PMID: 17545534 Clinical Trial.
Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers.
Herbertson RA, Tebbutt NC, Lee FT, MacFarlane DJ, Chappell B, Micallef N, Lee ST, Saunder T, Hopkins W, Smyth FE, Wyld DK, Bellen J, Sonnichsen DS, Brechbiel MW, Murone C, Scott AM. Herbertson RA, et al. Among authors: murone c. Clin Cancer Res. 2009 Nov 1;15(21):6709-15. doi: 10.1158/1078-0432.CCR-09-0536. Epub 2009 Oct 13. Clin Cancer Res. 2009. PMID: 19825951 Free PMC article. Clinical Trial.
Targeting EphA3 inhibits cancer growth by disrupting the tumor stromal microenvironment.
Vail ME, Murone C, Tan A, Hii L, Abebe D, Janes PW, Lee FT, Baer M, Palath V, Bebbington C, Yarranton G, Llerena C, Garic S, Abramson D, Cartwright G, Scott AM, Lackmann M. Vail ME, et al. Among authors: murone c. Cancer Res. 2014 Aug 15;74(16):4470-81. doi: 10.1158/0008-5472.CAN-14-0218. Cancer Res. 2014. PMID: 25125683
50 results